Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2018

  • ID: 4473287
  • Drug Pipelines
  • 90 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • NicOx SA
  • Novan Inc
  • SynZyme Technologies LLC
  • Topadur Pharma AG
  • MORE
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H1 2018

Summary:

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble Guanylate Cyclase - Pipeline Review, H1 2018, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 4, 3, 13 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Cardiovascular, Metabolic Disorders, Ophthalmology, Central Nervous System, Gastrointestinal, Hematological Disorders, Immunology, Infectious Disease, Oncology, Respiratory, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones and Toxicology which include indications Ocular Hypertension, Glaucoma, Diabetic Nephropathy, Pulmonary Hypertension, Sickle Cell Disease, Tinea pedis (Athlete Foot), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Carotid Artery Stenosis, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Cystic Fibrosis, Diabetic Foot Ulcers, Diabetic Neuropathic Pain, Diastolic Heart Failure, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Lung Infections, Onychomycosis (Tinea Unguium), Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Arterial Hypertension, Stroke, Systemic Sclerosis (Scleroderma), Systolic Heart Failure, Vascular Dementias and Wounds.

Furthermore, this report also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Boehringer Ingelheim GmbH
  • NicOx SA
  • Novan Inc
  • SynZyme Technologies LLC
  • Topadur Pharma AG
  • MORE
Introduction

Report Coverage

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development

Bayer AG

Boehringer Ingelheim GmbH

Ironwood Pharmaceuticals Inc

NicOx SA

Novan Inc

SynZyme Technologies LLC

Topadur Pharma AG

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles

A-8R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1101042 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1237592 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-546544 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-703704 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyurea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IW-1701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IW-6463 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IWP-953 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naproxcinod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-1653 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-470 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCX-667 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

praliciguat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

riociguat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate sGC for Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Hypertension and Parenchymal Hemorrhage - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate sGC for Liver Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOPN-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vacno - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vericiguat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones

Featured News & Press Releases

Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease

Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects

Oct 31, 2017: Novoteris Investigator Receives Health Canada Clearance to Start a Phase 2a Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Non-Tuberculous Mycobacteria

Oct 24, 2017: Bayer to Present Pulmonary Arterial Hypertension Data at the 2017 Annual Meeting of the American College of Chest Physicians

Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study

Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis

May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference

May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017

May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017

Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017

Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

Jan 26, 2017: Bayer and Merck to Present Riociguat Data in Rare Pulmonary Diseases at the Annual World Congress of the Pulmonary Vascular Research Institute

Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Bayer AG, H1 2018

Pipeline by Boehringer Ingelheim GmbH, H1 2018

Pipeline by Ironwood Pharmaceuticals Inc, H1 2018

Pipeline by NicOx SA, H1 2018

Pipeline by Novan Inc, H1 2018

Pipeline by SynZyme Technologies LLC, H1 2018

Pipeline by Topadur Pharma AG, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Dormant Products, H1 2018 (Contd..3), H1 2018

Discontinued Products, H1 2018

List of Figures:

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ironwood Pharmaceuticals Inc
  • NicOx SA
  • Novan Inc
  • SynZyme Technologies LLC
  • Topadur Pharma AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll